Through immunohistochemical analysis, this study revealed a substantial percentage of 75.6% of ameloblastomas harboring mutations in BRAF V600E, with the highest significance observed in unicystic cases, where 90% of them tested positive for this mutation. The gene discussed is BRAF; the disease is ameloblastoma.